Daily Stock Analysis, ARGS, Argos Therapeutics Inc, priceseries

Argos Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
0.39
Close
0.34
High
0.43
Low
0.32
Previous Close
1.10
Daily Price Gain
-0.76
YTD High
4.00
YTD High Date
Jan 4, 2018
YTD Low
0.32
YTD Low Date
Apr 19, 2018
YTD Price Change
-2.76
YTD Gain
-89.10%
52 Week High
12.00
52 Week High Date
Apr 20, 2017
52 Week Low
0.32
52 Week Low Date
Apr 19, 2018
52 Week Price Change
-9.22
52 Week Gain
-96.47%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Oct 9. 2017
3.92
Oct 10. 2017
4.35
1 Trading Days
10.97%
Link
LONG
Nov 8. 2017
3.17
Nov 14. 2017
3.51
4 Trading Days
10.80%
Link
Company Information
Stock Symbol
ARGS
Exchange
NasdaqGM
Company URL
http://www.argostherapeutics.com
Company Phone
9192876300
CEO
Jeffrey D. Abbey
Headquarters
North Carolina
Business Address
4233 TECHNOLOGY DR, DURHAM, NC 27704
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001105533
About

Argos Therapeutics, Inc. is a biopharmaceutical company, which engages in development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its proprietary technology platform called Arcelis. Its product candidates include AGS-003 for the treatment of metastatic renal cell carcinoma, and other cancers; and AGS-004 for the treatment of human immunodeficiency virus. The company was founded by Ralph Steinman on May 8, 1997 and is headquartered in Durham, NC.

Description

Argos Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of personalized immunotherapies for the treatment of cancer and infectious diseases. The company develops immunotherapies based on Arcelis, its proprietary technology platform. Its products include AGS-003, which is under Phase III clinical trials and intended for the treatment of metastatic renal cell carcinoma (clear cell); and AGS-004, which is under Phase IIb clinical trials and is intended for the treatment of Human Immunodeficiency Virus. The company also develops AGS-003 for metastatic renal cell carcinoma (non-clear cell), early stage RCC, and other solid tumors. The company was formerly known as Merix Bioscience, Inc. and changed its name to Argos Therapeutics, Inc. in October 2004. Argos Therapeutics, Inc. was founded in 1997 and is headquartered in Durham, North Carolina.